Senzime (SEZI) Stock Overview
A medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SEZI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Senzime AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.81 |
| 52 Week High | SEK 7.38 |
| 52 Week Low | SEK 3.60 |
| Beta | 0.39 |
| 1 Month Change | -10.93% |
| 3 Month Change | -29.26% |
| 1 Year Change | -18.75% |
| 3 Year Change | -59.17% |
| 5 Year Change | -78.14% |
| Change since IPO | -44.07% |
Recent News & Updates
Recent updates
Is Senzime (STO:SEZI) In A Good Position To Invest In Growth?
Dec 06
US And European EMG Guidelines Will Spur TetraGraph Adoption
Mandated EMG technology in Europe and the U.S. and new product launches set a strong growth trajectory, boosting sales and revenue.We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth
Mar 19Will Senzime (STO:SEZI) Spend Its Cash Wisely?
Feb 20We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth
Sep 01Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth
May 18How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own?
Mar 15Shareholder Returns
| SEZI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -4.4% | -0.6% | 1.0% |
| 1Y | -18.8% | -21.7% | 2.0% |
Return vs Industry: SEZI exceeded the Swedish Medical Equipment industry which returned -21.7% over the past year.
Return vs Market: SEZI underperformed the Swedish Market which returned 2% over the past year.
Price Volatility
| SEZI volatility | |
|---|---|
| SEZI Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: SEZI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SEZI's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 54 | Philip Siberg | www.senzime.com |
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe.
Senzime AB (publ) Fundamentals Summary
| SEZI fundamental statistics | |
|---|---|
| Market cap | SEK 756.20m |
| Earnings (TTM) | -SEK 120.62m |
| Revenue (TTM) | SEK 89.71m |
Is SEZI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEZI income statement (TTM) | |
|---|---|
| Revenue | SEK 89.71m |
| Cost of Revenue | SEK 52.15m |
| Gross Profit | SEK 37.56m |
| Other Expenses | SEK 158.18m |
| Earnings | -SEK 120.62m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 18, 2026
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 41.86% |
| Net Profit Margin | -134.46% |
| Debt/Equity Ratio | 0% |
How did SEZI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 01:14 |
| End of Day Share Price | 2025/12/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Senzime AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oscar Stjerngren | Danske Bank |
| Klas Palin | DNB Carnegie Commissioned Research |
| Gustaf Meyer | Redeye |